Evelo Biosciences (OTCPK:EVLO) - Stock Price, News & Analysis

EVLO Stock Overview

EVLO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Rewards

Risk Analysis

Cotización muy volátil en los últimos 3 meses

Fondos propios negativos

Tiene unos ingresos inferiores a 1 millón de dólares ($0)

Tiene menos de 1 año de cash runway

+ 3 more risks

Evelo Biosciences, Inc. Competitors

Bellerophon Therapeutics

OTCPK:BLPH

US$672.8k

RegenETP

OTCPK:RGTP.Q

US$718.6k

Capstone Holding

OTCPK:CAPS

US$819.6k

Vyant Bio

OTCPK:VYNT

US$1.1m

Price History & Performance

Summary of all time highs, changes and price drops for Evelo Biosciences
Historical stock prices
Current Share Price	US$0.035
52 Week High	US$13.93
52 Week Low	US$0.028
Beta	2.03
1 Month Change	-43.55%
3 Month Change	-41.67%
1 Year Change	-99.05%
3 Year Change	-99.98%
5 Year Change	-99.98%
Change since IPO	-99.99%

Recent updates

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

Mar 11

Evelo Bio secures ~$67.5M capital raise

Jan 29

Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis

Jan 07

Trade Alert: The Independent Chairman Of Evelo Biosciences, Inc. (NASDAQ:EVLO), David Epstein, Has Just Spent US$51k Buying 77% More Shares

Dec 15

Do Institutions Own Evelo Biosciences, Inc. (NASDAQ:EVLO) Shares?

Dec 11

Evelo Biosciences identifies new lead oncology candidate

Dec 09

Evelo Bio's EDP1815 completes enrollment targeting interim data in mid-stage psoriasis study

Dec 03

Evelo Biosciences EPS beats by $0.04

Oct 29

Shareholder Returns

	EVLO	US Biotechs	US Market
7D	-22.2%	-4.5%	-1.0%
1Y	-99.1%	3.6%	26.0%

Rentabilidad frente al sector: EVLO obtuvo unos resultados inferiores a los del sector US Biotechs , que el año pasado arrojó un rendimiento del 4.4%.

Rentabilidad vs. Mercado: EVLO obtuvo unos resultados inferiores a los del mercado US, que fue del 20.5% el año pasado.

Price Volatility

Is EVLO's price volatile compared to industry and market?
EVLO volatility
EVLO Average Weekly Movement	29.3%
Biotechs Industry Average Movement	12.1%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: EVLOha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: EVLOha disminuido de 38% a 30% en el último año, pero sigue siendo superior al 75% de los valores de US.

About the Company

Founded	Employees	CEO	Website
2014	66	n/a	https://www.evelobio.com

Evelo Biosciences, Inc, empresa biotecnológica en fase clínica, se centra en el descubrimiento y desarrollo de medicamentos orales que actúan sobre las células inmunitarias del intestino delgado con efectos sistémicos. Está desarrollando EDP1815, un producto candidato a microbio completo, que ha completado un ensayo de fase 2 para el tratamiento de la psoriasis; y está en fase 2 de ensayo clínico para el tratamiento de la dermatitis atópica. La empresa también está desarrollando EDP1867, un preparado farmacéutico no vivo para una cepa única de Veillonella parvula, que se encuentra en la fase 1b de ensayo clínico; EDP2939, un biológico oral en investigación para el tratamiento potencial de enfermedades inflamatorias; y EDP1908, un producto candidato para oncología.

Evelo Biosciences, Inc. Fundamentals Summary

How do Evelo Biosciences's earnings and revenue compare to its market cap?
EVLO fundamental statistics
Market cap	US$664.40k
Earnings (TTM)	-US$82.35m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is EVLO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EVLO income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$82.35m
Earnings	-US$82.35m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)	-4.34
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	-127.1%

How did EVLO perform over the long term?

See historical performance and comparison

EVLO Stock Overview

Rewards

Risk Analysis

Evelo Biosciences, Inc. Competitors

OTCPK:BLPH

US$672.8k

OTCPK:RGTP.Q

US$718.6k

OTCPK:CAPS

US$819.6k

OTCPK:VYNT

US$1.1m

Price History & Performance

Recent News & Updates

Evelo Biosciences, Inc. Files Form 15

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index

Evelo Biosciences Provides Non-Compliance Update

Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis

Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering

Recent updates

Evelo Biosciences, Inc. Files Form 15

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from S&P TMI Index

Evelo Biosciences, Inc.(OTCPK:EVLO) dropped from NASDAQ Biotechnology Index

Evelo Biosciences Provides Non-Compliance Update

Evelo Biosciences, Inc. Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis

Evelo Biosciences, Inc. announced that it has received $25.468522 million in funding from FMR LLC, Flagship Pioneering

Evelo Biosciences, Inc. Announces Management Changes

Evelo Biosciences, Inc. Announces Management Changes

Evelo Biosciences Announces Reverse Stock Split to Meet the Minimum Per Share Bid Price Requirement for Continued Listing on the Nasdaq Global Select Market

Evelo Biosciences, Inc. Eliminates Position of Jonathan Zung, Chief Development Officer

David R. Epstein Intends to Resign from Evelo Biosciences, Inc.'s Board

Evelo Biosciences, Inc. Announces Executive Changes

Evelo Biosciences, Inc. Announces Updates to its Clinical Pipeline

Price target decreased to US$8.00

High number of new directors

Is Evelo Biosciences (NASDAQ:EVLO) Using Debt In A Risky Way?

Evelo Biosciences, Inc. Plans to Replace President Simba Gill

Evelo Biosciences, Inc. Announces Two Phase 2 Clinical Read-Outs with EDP1815 in Atopic Dermatitis Expected in First quarter and Second Quarter 2023; Phase 2 Data for EDP2939 in Psoriasis expected in Second Half 2023

Evelo Biosciences GAAP EPS of -$0.40 beats by $0.03

Evelo Biosciences, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Evelo Biosciences, Inc. Appoints Marella Thorell as the Chief Financial Officer Effective from September 1, 2022

Marella Thorell is the new finance chief of Evelo Biosciences

Evelo Biosciences, Inc.(NasdaqGS:EVLO) dropped from Russell 2000 Dynamic Index

Evelo Biosciences: Hope After Dilution?

Evelo Biosciences, Inc. Announces Executive Changes

High number of new directors

High number of new directors

Price target decreased to US$15.40

David P. Perry Not Stand for Re-Election to Board of Directors of Evelo Biosciences, Inc

Evelo Biosciences, Inc. Plans to Meet with Health Authorities to Discuss the Path Forward to Registration Trials for EDP1815 in Patients with Psoriasis

Price target increased to US$22.50

Evelo Biosciences, Inc. Announces Executive Appointments

Evelo Biosciences (NASDAQ:EVLO) Has Debt But No Earnings; Should You Worry?

Evelo Biosciences, Inc. Announces Data from Post-Treatment Follow-Up (Part B) of its Phase 2 Trial of EDP1815 in Mild and Moderate Psoriasis

Evelo Biosciences Announces Dosing of First Patient in Phase 2 Trial of EDP1815 in Atopic Dermatitis

Evelo Biosciences Announces Highly Significant Reductions in Clinically Validated Inflammatory Cytokines in Edp1815 Phase 2 Psoriasis Trial

Price target increased to US$23.70

Evelo Biosciences Presents Data on EDP1815 Mechanism of Action and Supporting Ongoing Clinical Development for Inflammatory Diseases

Evelo Biosciences, Inc. Announces Updates of Phase 2 Clinical Trial of EDP1815 in Atopic Dermatitis and Phase 1B Clinical Data with EDP1815 in Atopic Dermatitis

High number of new directors

High number of new directors

Evelo Biosciences, Inc. Announces Positive Data from Its Phase 2 Study Evaluating EDP1815 Versus Placebo for the Treatment of Mild and Moderate Psoriasis

Is Evelo Biosciences (NASDAQ:EVLO) Weighed On By Its Debt Load?

Price target increased to US$23.33

Evelo Biosciences Presents New Preclinical Data for Extracellular Vesicle Anti-Inflammatory Product Candidate Edp2939 at the American Association of Immunologists Meeting

What Type Of Shareholders Make Up Evelo Biosciences, Inc.'s (NASDAQ:EVLO) Share Registry?

Evelo Biosciences, Inc. to Report Q4, 2020 Results on Mar 09, 2021

Appoints John A. Hohneker, M.D. to Board of Directors

Evelo Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $67.5 million.

Evelo Bio secures ~$67.5M capital raise

New 90-day high: US$18.60

Evelo Biosciences, Inc. Updates Data Following Completion of the Mild and Moderate Atopic Dermatitis Cohort in Its Phase 1B Clinical Trial

New 90-day high: US$13.89

Evelo Biosciences Expands Clinical Programs

Evelo Biosciences expands EDP1815 mid-stage trial to atopic dermatitis

New 90-day high: US$12.28

Evelo Biosciences, Inc. Appoints Jonathan Zung as Chief Development Officer

Evelo Biosciences, Inc. Enters into Development and Clinical Master Services Agreement with Halo Pharmaceutical, Inc

Evelo Biosciences, Inc. Updates on Its Clinical Trails